Aurobindo Pharma (Large Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Aurobindo Pharma Limited |
|||
|
Price: ₹1,115.15 (-0.54%) | ||
| 52 Week Low: ₹984.30 52 Week High: ₹1,592.00 |
|||
| Market Capital: 72,606.05 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Aurobindo Pharma Share Price Target For 2025
- 1.1.1: Aurobindo Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Aurobindo Pharma Share Price Target For 2026
- 1.2.1: Aurobindo Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Aurobindo Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Aurobindo Pharma Brief Company Overview
- 4: Aurobindo Pharma Financial Performance
- 4.0.1: Is Aurobindo Pharma A Good Buy For Long Term?
Aurobindo Pharma, a Large Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 127.4% returns in 5-year showing 8.0% quarterly revenue growth with 11.8% profit margin, making it a potential Multibagger.
To predict the Aurobindo Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Aurobindo Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Aurobindo Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Aurobindo Pharma shares in 2025, see the table below.
Aurobindo Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1224.05 (+9.76%) | Price Action: 11 Dec 2024 Low |
| 2025 Target 2 | 1209.7 (+8.47%) | Price Action: 06 Feb 2025 High |
| 2025 Target 1 | 1196.9 (+7.33%) | Price Action: 30 May 2024 Low |
| Current Price | 1115.15 | Aurobindo Pharma's share price as of 21 Feb 2025 |
| Stop Loss 1 | 1077.65 (-3.37%) | Price Action: 03 Jan 2024 Low |
| Stop Loss 2 | 1064.05 (-4.59%) | Price Action: 28 Mar 2024 Low |
| Stop Loss 3 | 1053.0 (-5.58%) | Price Action: 27 Feb 2024 High |
Short-Term Technical Outlook
Current Technical Position: Aurobindo Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹1168.85 serves as the nearest technical reference point.
Historical Returns: 3-month: -11.68% | 6-month: -28.94% | 1-year: +8.47%
Aurobindo Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Aurobindo Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Aurobindo Pharma shares in 2026, see the table below.
Aurobindo Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1831.14 (+64.2%) | Fibonacci Extension Level 123.60% |
| 2026 Target 2 | 1790.52 (+60.56%) | Price Action: Chart |
| 2026 Target 1 | 1772.79 (+58.97%) | Fibonacci Extension Level 64.90% |
| Current Price | 1115.15 | Aurobindo Pharma's share price as of 21 Feb 2025 |
| Stop Loss 1 | 961.85 (-13.75%) | Price Action: 15 Nov 2023 Low |
| Stop Loss 2 | 947.7 (-15.02%) | Price Action: 08 Nov 2023 High |
| Stop Loss 3 | 929.3 (-16.67%) | Price Action: 09 Nov 2023 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Aurobindo Pharma is currently trading near its 52-week low of ₹984.3, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +8.47% | 3-year: +81.81% | 5-year: +127.42%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Aurobindo Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,115.15 | ||
| 2025 | ₹1,844.63 | +65.41% | ₹1,872.30 |
| 2026 | ₹2,382.03 | +29.13% | ₹2,417.76 |
| 2027 | ₹2,944.80 | +23.62% | ₹2,988.97 |
| 2028 | ₹4,152.35 | +41% | ₹4,214.64 |
| 2029 | ₹5,473.22 | +31.81% | ₹5,555.32 |
| 2030 | ₹7,193.40 | +31.42% | ₹7,301.30 |
| 2031 | ₹9,009.71 | +25.24% | ₹9,144.86 |
| 2032 | ₹11,763.34 | +30.56% | ₹11,939.79 |
| 2033 | ₹14,594.48 | +24.06% | ₹14,813.40 |
| 2034 | ₹17,365.70 | +18.98% | ₹17,626.19 |
| 2035 | ₹20,386.92 | +17.39% | ₹20,692.72 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Aurobindo Pharma Brief Company Overview
Aurobindo Pharma Limited: A Leading Pharmaceutical Company Key Products and Services: Generic formulations, active pharmaceutical ingredients (API), antiretroviral drugs, biocatalysts, and contract services covering the entire drug lifecycle History and Market...
Presence: Founded in 1986, headquartered in Hyderabad, India; operates in India, the US, Europe, and internationally Reputation: Renowned in the industry for its diverse product range and commitment to quality Commitment: Dedicated to providing affordable and accessible healthcare solutionsAurobindo Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 72,606.05 Crore | Market valuation of Aurobindo Pharma's shares. |
| Revenue (TTM) | 30,295.01 Crore | Total revenue generated by Aurobindo Pharma over the past twelve months. |
| Net Income (TTM) | +3,581.63 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +15.18% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +11.82% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+8% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+8% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
27.28 | Company's total debt divided by total shareholder equity. |
| Total Debt | 8,427.24 Crore | Sum of Aurobindo Pharma's current & long-term financial obligations. |
| Total Cash | 6,868.23 Crore | Total amount of liquid funds available to Aurobindo Pharma. |
| Beta | 0.59 | Beta is less than 1 indicating that the Aurobindo Pharma's price is less volatile than the market. |
Is Aurobindo Pharma A Good Buy For Long Term?
Aurobindo Pharma, a large-cap stock with a market capitalization of ₹72,606.05 crore, shows mixed signals. While its ₹3,581.63 crore net profit (11.82% margin) on ₹30,295.01 crore revenue in the last 12 months is positive, a significant debt of ₹8,427.24 crore (Q2 2024-25) offsets the ₹6,868.23 crore cash balance. Past performance (YTD: 12.88%, 3-year: 32.89%, 5-year: 67.41%) is strong, but recent 3-month returns are negative (-14.68%). Considering this, Aurobindo Pharma is an average buy for the long term, warranting further in-depth analysis before investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
